This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Drug giants eye China for deals despite growing Sino-US tensions RE
Sanofi: new offers for Consumer Healthcare? CF
Advent International, PAI Partners Among First-Round Bidders for Sanofi's Consumer Health Division MT
Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms MT
Sanofi Executive Expresses Optimism in China's Immunology Industry MT
Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms MT
Sanofi: positive data for hemophilia in children CF
Sanofi's Consumer Health Unit Gets Initial Bids from Private Equity Firms MT
Sanofi to invest $437 million in India global centre, double its workforce RE
EU court criticizes Commission over handling of COVID vaccine contracts RE
SANOFI : JP Morgan remains Neutral ZD
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market RE
Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale MT
Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season CI
SANOFI : Receives a Sell rating from Deutsche Bank ZD
SANOFI : UBS reiterates its buy recommendation CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday MT
SANOFI : UBS maintains a Buy rating ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy CI
SANOFI : Jefferies maintains a Buy rating ZD
SANOFI : Stifel slightly raises its target on the stock CF
That's not so bad, is it? Our Logo
Chart Sanofi
More charts
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Employees
86,088
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
93.57EUR
Average target price
108.56EUR
Spread / Average Target
+16.02%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis